[
  {
    "ts": null,
    "headline": "Pfizer's Golden Cross Signals Strength: How to Play the Stock",
    "summary": "Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.",
    "url": "https://finnhub.io/api/news?id=766b7bbe3cfaf3f14842b487bb761254e5a7e1e7add1dbf89f118fba2d7c5ac2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756745940,
      "headline": "Pfizer's Golden Cross Signals Strength: How to Play the Stock",
      "id": 136604057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.",
      "url": "https://finnhub.io/api/news?id=766b7bbe3cfaf3f14842b487bb761254e5a7e1e7add1dbf89f118fba2d7c5ac2"
    }
  },
  {
    "ts": null,
    "headline": "NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?",
    "summary": "Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.",
    "url": "https://finnhub.io/api/news?id=ceb21b4812e5cfe77c54ab66cfe1da8cd81e2d4678188228fb78195e689b8daa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756742040,
      "headline": "NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?",
      "id": 136604058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.",
      "url": "https://finnhub.io/api/news?id=ceb21b4812e5cfe77c54ab66cfe1da8cd81e2d4678188228fb78195e689b8daa"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi",
    "summary": "BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.",
    "url": "https://finnhub.io/api/news?id=5fcb22efe784c3c1bc1390055a3abba44f55bffbec9fbdb7de18c979e53736ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756740660,
      "headline": "Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi",
      "id": 136604059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.",
      "url": "https://finnhub.io/api/news?id=5fcb22efe784c3c1bc1390055a3abba44f55bffbec9fbdb7de18c979e53736ab"
    }
  },
  {
    "ts": null,
    "headline": "ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events",
    "summary": "In the real-world trial, Novo Nordisk's Wegovy showed a significant reduction in cardiovascular events compared to Eli Lilly’s Zepbound.",
    "url": "https://finnhub.io/api/news?id=3ca7ef78fa9f953fb29a971b405c7612e31a7433f4952cfbca51e7bc9f9b467c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756731308,
      "headline": "ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events",
      "id": 136596084,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the real-world trial, Novo Nordisk's Wegovy showed a significant reduction in cardiovascular events compared to Eli Lilly’s Zepbound.",
      "url": "https://finnhub.io/api/news?id=3ca7ef78fa9f953fb29a971b405c7612e31a7433f4952cfbca51e7bc9f9b467c"
    }
  },
  {
    "ts": null,
    "headline": "ESC 2025: Study supports use of semaglutide, tirzepatide in cardiometabolic HFpEF patients",
    "summary": "The findings presented highlighted that patients initiating semaglutide or tirzepatide had more than 40 % lower risk of hospitalisation for heart failure (HF) or all-cause mortality compared to sitagliptin.",
    "url": "https://finnhub.io/api/news?id=0283f3e9222ff393de1a50a83ce101d42fae671e9af6febe4915124c7b2cd6cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756728697,
      "headline": "ESC 2025: Study supports use of semaglutide, tirzepatide in cardiometabolic HFpEF patients",
      "id": 136596085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The findings presented highlighted that patients initiating semaglutide or tirzepatide had more than 40 % lower risk of hospitalisation for heart failure (HF) or all-cause mortality compared to sitagliptin.",
      "url": "https://finnhub.io/api/news?id=0283f3e9222ff393de1a50a83ce101d42fae671e9af6febe4915124c7b2cd6cd"
    }
  },
  {
    "ts": null,
    "headline": "Novo’s Wegovy Beats Lilly’s Zepbound for Heart Health, Study Finds. What It Means for Stocks.",
    "summary": "The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.",
    "url": "https://finnhub.io/api/news?id=ff30bdfce7f96c9d9152efa62b603294032f0d2a612e0101c392295df9cc4de3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756726740,
      "headline": "Novo’s Wegovy Beats Lilly’s Zepbound for Heart Health, Study Finds. What It Means for Stocks.",
      "id": 136596086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.",
      "url": "https://finnhub.io/api/news?id=ff30bdfce7f96c9d9152efa62b603294032f0d2a612e0101c392295df9cc4de3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY): Revisiting Valuation as Investors Reassess Outlook Without Major News",
    "summary": "Eli Lilly (LLY) has landed back on investor radars after its stock movement sparked new debates, even in the absence of a major headline event. Sometimes it is the quiet moments that catch the market’s attention, prompting fresh questions around what the next chapter looks like for a company of this scale and ambition. With no major news item steering the action, the focus shifts to the company’s fundamentals and whether today’s price truly holds up against future potential. Putting the...",
    "url": "https://finnhub.io/api/news?id=39cc5b1430e812d85674f6b24396b9c5aa93e5eb3e3ee7f82cf4ccdeb0753681",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756724908,
      "headline": "Eli Lilly (LLY): Revisiting Valuation as Investors Reassess Outlook Without Major News",
      "id": 136596087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has landed back on investor radars after its stock movement sparked new debates, even in the absence of a major headline event. Sometimes it is the quiet moments that catch the market’s attention, prompting fresh questions around what the next chapter looks like for a company of this scale and ambition. With no major news item steering the action, the focus shifts to the company’s fundamentals and whether today’s price truly holds up against future potential. Putting the...",
      "url": "https://finnhub.io/api/news?id=39cc5b1430e812d85674f6b24396b9c5aa93e5eb3e3ee7f82cf4ccdeb0753681"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Alibaba, BYD, Novo Nordisk, bitcoin and BAE",
    "summary": "The latest investor updates on stocks that are trending on Monday",
    "url": "https://finnhub.io/api/news?id=942441bfdd061b9539d6dfc775bafa93d983af66cb7bd760c6c5281b4b745b23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756715980,
      "headline": "Trending tickers: Alibaba, BYD, Novo Nordisk, bitcoin and BAE",
      "id": 136595105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Monday",
      "url": "https://finnhub.io/api/news?id=942441bfdd061b9539d6dfc775bafa93d983af66cb7bd760c6c5281b4b745b23"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug",
    "summary": "The study used evidence gathered from patient experiences rather than a controlled trial, Novo said.",
    "url": "https://finnhub.io/api/news?id=4782499436164dd164a80caa382ad5afd536140de7310d8af2e1d1292ec55dab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756715400,
      "headline": "Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug",
      "id": 136596089,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The study used evidence gathered from patient experiences rather than a controlled trial, Novo said.",
      "url": "https://finnhub.io/api/news?id=4782499436164dd164a80caa382ad5afd536140de7310d8af2e1d1292ec55dab"
    }
  }
]